PriceTargets.com logo

Agios Pharmaceuticals - AGIO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $52.33
  • Forecasted Upside: -9.82%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$58.03 As of 12/3/2024 12:32 PM ET
▼ -0.84 (-1.43%)

This chart shows the closing price for AGIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Agios Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGIO

Analyst Price Target is $52.33
▼ -9.82% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Agios Pharmaceuticals in the last 3 months. The average price target is $52.33, with a high forecast of $56.00 and a low forecast of $46.00. The average price target represents a -9.82% upside from the last price of $58.03.

This chart shows the closing price for AGIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Agios Pharmaceuticals. This rating has held steady since October 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/1/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$55.00 ➝ $55.00
11/1/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$51.00 ➝ $53.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$51.00
10/10/2024Raymond JamesReiterated RatingOutperform$51.00
9/27/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
9/27/2024Leerink PartnersDowngradeOutperform ➝ Market Perform$60.00 ➝ $56.00
9/20/2024Cantor FitzgeraldReiterated RatingOverweight
9/19/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$55.00 ➝ $55.00
8/2/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$53.00 ➝ $55.00
6/17/2024Cantor FitzgeraldReiterated RatingOverweight
6/13/2024JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Neutral$46.00
6/4/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$33.00 ➝ $53.00
6/4/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$44.00 ➝ $53.00
5/3/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$29.00 ➝ $33.00
4/9/2024Cantor FitzgeraldReiterated RatingOverweight
2/23/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$31.00 ➝ $30.00
2/16/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$43.00 ➝ $42.00
2/8/2024Cantor FitzgeraldReiterated RatingOverweight
11/3/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$32.00 ➝ $28.00
8/7/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$33.00 ➝ $32.00
5/5/2023SVB SecuritiesLower Target$37.00 ➝ $34.00
2/3/2023Piper SandlerInitiated CoverageOverweight$41.00
2/3/2023Piper Sandler CompaniesInitiated CoverageOverweight$41.00
11/17/2022The Goldman Sachs GroupUpgradeSell ➝ Neutral$17.00 ➝ $32.00
8/5/2022Leerink PartnersBoost TargetOutperform$33.00 ➝ $37.00
7/27/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$33.00
5/24/2022The Goldman Sachs GroupLower TargetSell$20.00 ➝ $16.00
5/17/2022Leerink PartnersBoost TargetMarket Perform$33.00
3/7/2022The Goldman Sachs GroupLower TargetSell$37.00 ➝ $23.00
3/3/2022HC WainwrightLower TargetBuy$98.00 ➝ $96.00
2/25/2022Royal Bank of CanadaBoost TargetOutperform$61.00 ➝ $67.00
2/24/2022HC WainwrightLower TargetBuy$98.00 ➝ $96.00
2/22/2022Leerink PartnersLower TargetMarket Perform$32.00 ➝ $30.00
2/18/2022HC WainwrightBoost TargetBuy$95.00 ➝ $98.00
2/16/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$52.00 ➝ $44.00
12/3/2021Bank of AmericaInitiated CoverageBuy$54.00
11/18/2021Leerink PartnersLower TargetMarket Perform$50.00 ➝ $42.00
11/4/2021HC WainwrightBoost TargetBuy$93.00 ➝ $95.00
7/30/2021Leerink PartnersInitiated CoverageHold$50.00
7/30/2021HC WainwrightBoost TargetBuy$88.00 ➝ $93.00
7/30/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$58.00 ➝ $39.00
6/30/2021Raymond JamesInitiated CoverageMarket Perform
6/13/2021OppenheimerReiterated RatingHold
6/10/2021HC WainwrightInitiated CoverageBuy$88.00
4/30/2021The Goldman Sachs GroupInitiated CoverageNeutral
4/30/2021BarclaysBoost TargetPositive ➝ Overweight$65.00 ➝ $70.00
3/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$54.00
3/4/2021Leerink PartnersReiterated RatingOutperform ➝ Market Perform$55.00 ➝ $50.00
3/1/2021Leerink PartnersUpgradeMarket Perform ➝ Outperform
3/1/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$64.00 ➝ $54.00
2/26/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$55.00 ➝ $50.00
1/27/2021Leerink PartnersBoost TargetOutperform$51.00 ➝ $55.00
1/27/2021BarclaysBoost TargetPositive ➝ Overweight$58.00 ➝ $65.00
1/14/2021BarclaysBoost Target$50.00 ➝ $58.00
12/22/2020Leerink PartnersLower Target$61.00 ➝ $51.00
12/22/2020Royal Bank of CanadaLower Target$59.00 ➝ $66.00
12/21/2020Piper SandlerBoost Target$73.00 ➝ $80.00
12/9/2020BMO Capital MarketsLower Target$57.00 ➝ $50.00
12/9/2020Leerink PartnersLower TargetOutperform$67.00 ➝ $61.00
11/20/2020BarclaysBoost TargetOverweight$46.00 ➝ $50.00
11/19/2020Cantor FitzgeraldBoost TargetOverweight$68.00 ➝ $79.00
10/22/2020BarclaysUpgradeEqual Weight ➝ Overweight$46.00
10/19/2020Needham & Company LLCLower TargetBuy$71.00 ➝ $69.00
10/19/2020Leerink PartnersLower TargetPositive ➝ Outperform$72.00 ➝ $67.00
10/19/2020Piper SandlerLower TargetOverweight$80.00 ➝ $73.00
7/31/2020Cantor FitzgeraldBoost TargetOverweight$70.00 ➝ $72.00
7/30/2020Needham & Company LLCInitiated CoverageBuy$71.00
6/15/2020Leerink PartnersBoost TargetOutperform$70.00 ➝ $72.00
6/15/2020GuggenheimBoost TargetBuy$60.00 ➝ $66.00
6/15/2020CitigroupBoost TargetBuy$64.00 ➝ $75.00
6/15/2020OppenheimerReiterated RatingHold
6/12/2020Piper SandlerBoost TargetOverweight$70.00 ➝ $80.00
5/4/2020JPMorgan Chase & Co.Boost TargetOverweight$72.00 ➝ $82.00
4/30/2020OppenheimerReiterated RatingHold
4/30/2020Needham & Company LLCReiterated RatingBuy$71.00
3/4/2020BarclaysInitiated CoverageEqual Weight$50.00
3/4/2020CowenReiterated RatingBuy
2/17/2020Needham & Company LLCReiterated RatingBuy$71.00
2/14/2020Cantor FitzgeraldReiterated RatingOverweight$64.00 ➝ $70.00
2/13/2020CowenReiterated RatingBuy
2/13/2020OppenheimerReiterated RatingHold
1/31/2020JPMorgan Chase & Co.Reiterated RatingBuy
1/21/2020OppenheimerReiterated RatingHold
1/14/2020CowenReiterated RatingBuy
12/10/2019CowenReiterated RatingBuy
12/9/2019BMO Capital MarketsBoost TargetOutperform$45.00 ➝ $49.00
12/4/2019JPMorgan Chase & Co.Lower TargetOverweight$80.00 ➝ $68.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/7/2024
  • 9 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
6/6/2024
  • 8 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 9 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/5/2024
  • 9 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 17 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 8 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 14 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 14 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Agios Pharmaceuticals logo
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $58.03
Low: $57.45
High: $58.78

50 Day Range

MA: $48.94
Low: $40.50
High: $60.46

52 Week Range

Now: $58.03
Low: $20.96
High: $62.58

Volume

54,099 shs

Average Volume

690,698 shs

Market Capitalization

$3.31 billion

P/E Ratio

5.11

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Agios Pharmaceuticals?

The following Wall Street research analysts have issued reports on Agios Pharmaceuticals in the last twelve months: Cantor Fitzgerald, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Raymond James, Royal Bank of Canada, Scotiabank, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for AGIO.

What is the current price target for Agios Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Agios Pharmaceuticals in the last year. Their average twelve-month price target is $52.33, suggesting a possible downside of 9.8%. Leerink Partners has the highest price target set, predicting AGIO will reach $56.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $46.00 for Agios Pharmaceuticals in the next year.
View the latest price targets for AGIO.

What is the current consensus analyst rating for Agios Pharmaceuticals?

Agios Pharmaceuticals currently has 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AGIO.

What other companies compete with Agios Pharmaceuticals?

Other companies that are similar to Agios Pharmaceuticals include Sarepta Therapeutics, Dr. Reddy's Laboratories, Vaxcyte, Catalent and Qiagen. Learn More about companies similar to Agios Pharmaceuticals.

How do I contact Agios Pharmaceuticals' investor relations team?

Agios Pharmaceuticals' physical mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company's listed phone number is (617) 649-8600 and its investor relations email address is [email protected]. The official website for Agios Pharmaceuticals is www.agios.com. Learn More about contacing Agios Pharmaceuticals investor relations.